BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 35836797)

  • 1. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
    Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
    Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
    [No Abstract]   [Full Text] [Related]  

  • 2. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
    Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y
    Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
    Liao L; Song M; Li X; Tang L; Zhang T; Zhang L; Pan Y; Chouchane L; Ma X
    Cancer Res; 2017 Apr; 77(8):2090-2101. PubMed ID: 28330927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    Wang S; Iyer R; Han X; Wei J; Li N; Cheng Y; Zhou Y; Gao Q; Zhang L; Yan M; Sun Z; Fang D
    J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 38038129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
    Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
    Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
    Chen T; Dong Y; Wu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
    Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
    Yu Z; Dong X; Song M; Xu A; He Q; Li H; Ouyang W; Chouchane L; Ma X
    Int J Cancer; 2024 Feb; 154(4):723-737. PubMed ID: 37855385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms regulating PD-L1 expression on tumor and immune cells.
    Chen S; Crabill GA; Pritchard TS; McMiller TL; Wei P; Pardoll DM; Pan F; Topalian SL
    J Immunother Cancer; 2019 Nov; 7(1):305. PubMed ID: 31730010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
    Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z
    Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
    Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
    Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
    Sasidharan Nair V; Toor SM; Ali BR; Elkord E
    Expert Opin Ther Targets; 2018 Jun; 22(6):547-557. PubMed ID: 29702007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer.
    Yang H; Xue M; Su P; Zhou Y; Li X; Li Z; Xia Y; Zhang C; Fu M; Zheng X; Luo G; Wei T; Wang X; Ding Y; Zhu J; Zhuang T
    J Exp Clin Cancer Res; 2022 Dec; 41(1):364. PubMed ID: 36581998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
    Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.